DYN — Dyne Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818794 ·
Last close
$18.15
Market Cap
$3.00B
52W High
$21.43
52W Low
$14.00
ADV30
1,635,734
Next earnings
2026-07-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -125,276,000 | -120,854,000 | 1,079,950,000 | 753,102,000 | 214,895,000 |
| Dec 2025 | 0 | — | -116,129,000 | -111,955,000 | 1,186,958,000 | 893,369,000 | 214,829,000 |
| Sep 2025 | 0 | — | -113,892,000 | -108,041,000 | 867,059,000 | 573,610,000 | 175,276,000 |
| Jun 2025 | 0 | — | -115,791,000 | -110,857,000 | 728,992,000 | 485,040,000 | 157,547,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-403,207,000
Investing CF
$-28,751,000
Financing CF
$890,307,000
CapEx
$-20,710,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.54
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,396,142,000
Inventory
—
Receivables
—
ST Investments
$217,193,000
EBIT TTM
$-447,033,000
Pretax Income TTM
$-446,214,000
Interest Exp TTM
$6,192,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -468,184,000 | -446,214,000 | 1,186,958,000 | 214,829,000 | — | -403,207,000 |
| Dec 2024 | 0 | -343,886,000 | -317,418,000 | 691,234,000 | 61,396,000 | — | -292,369,000 |
| Dec 2023 | 0 | -242,162,000 | -235,937,000 | 165,082,000 | 73,790,000 | — | -188,158,000 |
| Dec 2022 | 0 | -170,962,000 | -168,099,000 | 306,325,000 | 53,961,000 | — | -153,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.98
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc. | $3.03B | $24.13 | — |
| TNGX | Tango Therapeutics, Inc. | $2.90B | $20.04 | — |
| GPCR | Structure Therapeutics Inc. | $2.81B | $39.58 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.79B | $21.57 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.24B | $9.57 | — |
News headlines (Yahoo Finance, 1h cache)
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
2026-05-26 11:30 · Yahoo
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
2026-05-21 15:31 · Yahoo
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone
2026-05-21 09:10 · Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-20 21:30 · Yahoo
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment
2026-05-20 12:33 · Yahoo
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
2026-05-20 11:46 · Yahoo
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 17:37 · Yahoo
Dyne Therapeutics to Participate in Upcoming Investor Conferences
2026-05-13 11:30 · Yahoo
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
2026-05-11 16:00 · Yahoo
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-11 11:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-05-22 16:10:03 | 2026-05-20 | Posner Brian S | Dir | P - Purchase | 17.12 | 2500 | 42800 |